Cutaneous T Cell Lymphoma clinical trials

Explore recruiting cutaneous t cell lymphoma clinical trials.

Recruiting cutaneous t cell lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cutaneous T Cell Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EORTC 1820-CLTF: Open-Label, phase II, Multi-Center, study of Anti-CCR4 Monoclonal Antibody (mogamulizumab) Plus Total Skin Electron Beam therapy (TSEB) in patients with stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)

Spain, Denmark, Italy, France, Germany, Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

An Open-Label, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PTX-100 Monotherapy in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma.

Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

An Investigator Initiated, descriptive, proof-of-concept, open-label pilot study targeting the tumor microenvironment and skin barrier deficiency through JAK1/3 inhibition

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Single-arm, Phase II Study to Evaluate the Efficacy and Safety of Linperlisib (YY-20394) Monotherapy in Patients with Relapsed or Refractory Peripheral T/NK Cell or Cutaneous T Cell Lymphoma

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

CITY

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Cutaneous T Cell Lymphoma trials by city

Cutaneous T Cell Lymphoma in Toronto Cutaneous T Cell Lymphoma in Vancouver Cutaneous T Cell Lymphoma in Montreal Cutaneous T Cell Lymphoma in Calgary Cutaneous T Cell Lymphoma in Edmonton Cutaneous T Cell Lymphoma in Ottawa Cutaneous T Cell Lymphoma in Winnipeg Cutaneous T Cell Lymphoma in Quebec City Cutaneous T Cell Lymphoma in Hamilton Cutaneous T Cell Lymphoma in Kitchener Cutaneous T Cell Lymphoma in London Cutaneous T Cell Lymphoma in Halifax Cutaneous T Cell Lymphoma in New York Cutaneous T Cell Lymphoma in Los Angeles Cutaneous T Cell Lymphoma in Chicago Cutaneous T Cell Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease